Class / Patent application number | Description | Number of patent applications / Date published |
514350000 | C=O bonded directly to the six-membered hetero ring | 62 |
20080200521 | Novel hydroxamic acid containing amino acid derivatives - Novel hydroxamic acid containing amino acid derivatives are provided that are useful for treatment of inflammation, inflammatory and immunological diseases; lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; and for treatment or prophylaxis of metabolic disorders. | 08-21-2008 |
20080227828 | Aryl Ureas With Angiogenisis Inhibiting Activity - This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes. | 09-18-2008 |
20080227829 | Neurogenic compounds - The invention relates to method(s) of use of the compound(s) described herein, e.g. method for stimulating neurogenesis, including in vitro neurogenesis, by contacting neuronal progenitor cells with an effective amount of the compound(s) described herein; method for treatment of a subject in need of treatment with a neurogenic compound; and/or for treatment of a disease or condition associated with damage to the hippocampus. The subject may be a human or a veterinary animal. | 09-18-2008 |
20080234332 | RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to Raf kinase inhibitors containing zinc-binding and their use in the treatment of Raf related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors. | 09-25-2008 |
20080242707 | Pharmaceutical Composition for the Treatment of Cancer - The present invention pertains to a pharmaceutical composition comprising the compound of the formula (I) in a high concentration and at least one pharmaceutically acceptable excipient, the use of the composition for the treatment of hyper-proliferative diseases, such as cancer, either as a sole agent, or in combination with other anti-cancer therapies, and the process for preparing of said composition. | 10-02-2008 |
20080280957 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof - Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds. | 11-13-2008 |
20080287508 | ALTERING PHARMACOKINETICS OF PIRFENIDONE THERAPY - The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl- | 11-20-2008 |
20090069388 | DEUTERIUM-ENRICHED SORAFENIB - The present application describes deuterium-enriched sorafenib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
20090124669 | Structural Analogues of Avenanthramides, Their Use in Compositions Useful in the Treatment of Dermatological Disorders - Novel compounds for the prevention and treatment of dermatological disorders with an immunoallergic, hyperproliferative and inflammatory component, and a method of producing such compounds. The compounds are bioisosteres of substances with avenanthramide structures. | 05-14-2009 |
20090131486 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL - The invention provides compounds of formula | 05-21-2009 |
20090192200 | POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF - Provided are sorafenib hemi-tosylate, polymorphs thereof, polymorphs of sorafenib tosylate, preparation thereof and pharmaceutical compositions thereof. | 07-30-2009 |
20090197922 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION - Compositions and methods of the invention are related to treating pulmonary hypertension using a Raf kinase inhibitor, such as sorafenib. IQ a particular aspect, pulmonary hypertension is pulmonary arterial hypertension. | 08-06-2009 |
20090197923 | METHOD OF PROVIDING PIRFENIDONE THERAPY TO A PATIENT - The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme. | 08-06-2009 |
20090215835 | TREATMENT OF CANCER WITH SORAFENIB - The present invention provides compositions and methods for treating specific cancers with effective amounts of sorafenib. | 08-27-2009 |
20090247588 | 2-TRIFLUOROMETHYLNICOTINAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS - The present invention relates to compounds formula I: | 10-01-2009 |
20090312373 | METHODS FOR THE TREATMENT OF CANCER USING PIPERLONGUMINE AND PIPERLONGUMINE ANALOGS - The invention provides methods for the treatment of cancer in a subject using piperlongumine and/or piperlongumine analogs. | 12-17-2009 |
20100063112 | POLYMORPH III OF 4-[4-(AMINO)-3-FLUOROPHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE - The present invention relates to the polymorph III of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders. | 03-11-2010 |
20100113533 | Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide - The present invention relates to the polymorph II of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders. | 05-06-2010 |
20100152251 | PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS - This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders. | 06-17-2010 |
20100160386 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS - The present invention relates to novel 4-phenoxy-6-phenyl- and 4-phenoxy-6-pyridylnicotinic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders, especially of dyslipidemias, arteriosclerosis and heart failure. | 06-24-2010 |
20100160387 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS - Compounds of the formula I: | 06-24-2010 |
20100160388 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS - Compounds of the formula I: | 06-24-2010 |
20100160389 | DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS - Compounds of the formula I: | 06-24-2010 |
20100173953 | 4-[4-(amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate - The present invention relates to 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders. | 07-08-2010 |
20100173954 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS - The present invention provides compositions and methods for treating cancer with DAST, 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide of the formula I, including all polymorphs, hydrates, pharmaceutically acceptable salts, metabolites, prodrugs, solvates or combinations thereof. | 07-08-2010 |
20100234432 | Substituted 6-phenylnicotinic acids and their use - The present application relates to novel substituted 6-phenylnicotinic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders, in particular dyslipidaemias, arteriosclerosis and heart failure. | 09-16-2010 |
20100261765 | MINERALOCORTICOID RECEPTOR MODULATORS - The present invention relates to dihydropyridine mineralocorticoid receptor modulating compounds having the structure: and their use in treating cardiovascular events. | 10-14-2010 |
20100267777 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS - The present invention provides compositions and uses thereof for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of DAST (4{4-[3-(4-chloro-3-trifluoromethylphenyf)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide.) | 10-21-2010 |
20110065759 | 5-(3,4-DICHLORO-PHENYL)-N-(2-HYDROXY-CYCLOHEXYL)-6-(2,2,2-TRIFLUORO-ETHOXY- )-NICOTINAMIDE AND SALTS THEREOF - The present invention relates to a compound of formula I, | 03-17-2011 |
20110098324 | PROLYL HYDROXYLASE INHIBITORS - The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I) | 04-28-2011 |
20110112153 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS - Compounds of the formula (I) are disclosed and are suitable for the treatment of seborrheic dermatitis. | 05-12-2011 |
20110178137 | DIARYL UREA FOR TREATING HEART FAILURE - The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing heart failure and/or connected diseases therewith comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide optionally combined with at least one additional therapeutic agent. | 07-21-2011 |
20110178138 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES - The present invention is directed to novel compounds. These compounds can be useful in inhibiting the activity of protein prenyltransferases including GGTase I and/or RabGGTase. The compounds can also be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits. | 07-21-2011 |
20110263657 | DIARYL UREAS FOR TREATING HEART FAILURE - The present invention relates to pharmaceutical compositions for treating, preventing or managing heart failure and/or connected diseases therewith comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound. | 10-27-2011 |
20120088801 | Pirfenidone Therapy and Inducers of Cytochrome P450 - The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. | 04-12-2012 |
20120108641 | ANTITUMOR COMBINATION INCLUDING AVE8062 AND SORAFENIB - Combinations comprising AVE8062 and sorafenib are provided which are effective in the treatment of cancers, more particularly of solid tumours. | 05-03-2012 |
20120149735 | 1,4-Dihydropyridine Derivatives and Their Uses - The present invention relates to 1,4-dihydropyridine derivatives of the formula (I) and their uses in the treatment and/or prevention of diseases and disorders directly or indirectly associated with the modification (increase or decrease) of the activity of the cannabinoid receptor 2 (CB2). | 06-14-2012 |
20120329836 | METHODS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER - Disclosed herein is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and the ester and amide prodrugs thereof, that can stabilize hypoxia inducible factor-2 alpha (HIF-2α) and thereby provide a method for treating cancer. Further disclosed are compositions which comprise {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and/or a prodrug thereof which can be used to treat cancer. | 12-27-2012 |
20130012550 | METHODS FOR PROGNOSIS AND MONITORING CANCER THERAPY - The present invention also relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of HER-2, EGFR, VEGF, u-PA, p-PAI-1, and soluble forms thereof, as biomarkers for cancer, especially for subjects treated with sorafenib. | 01-10-2013 |
20130131122 | Fluro substituted Omega-Carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions - A compound of Formula (I): | 05-23-2013 |
20130245075 | MELANOGENESIS INHIBITION-METHODS AND COMPOSITIONS THEREOF - The present invention relates to melanogenesis inhibition using an effective amount of piper longumine obtained from the roots of | 09-19-2013 |
20130245076 | PROLYL HYDROXYLASE INHIBITORS AND METHOD OF USE - The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. | 09-19-2013 |
20130338198 | COMPOSITION FOR TREATING DERMATITIS AND ICHTHYOSIS, AND METHOD FOR TREATING DERMATITIS AND ICHTHYOSIS - A skin disorder treatment composition and method for treating a skin disorder or symptoms of a skin disorder are provided. The composition includes: about 0.0001 wt. % to about 5 wt. % of a serine protease inhibitor; about 2 wt. % to about 10 wt. % of a hydrophobic polymer/hydrophilic polymer complex comprising a poly(vinylpyrrolidone-alkylene) polymer wherein the alkylene group contains at least 10 carbon atoms and a cellulose containing polymer; about 0.5 wt. % to about 20 wt. % of a release agent; and at least about 50 wt. % water. The skin disorder or the symptom of skin disorder from ichthyosis, dermatitis, eczema, rosacea, psoriasis, inflammation, xerosis, or urticaria. | 12-19-2013 |
20140051730 | THERAPEUTIC USE OF DIMIRACETAM TO PREVENT THE HAND AND FOOT SYNDROME CAUSED BY SORAFENIB - Dimiracetam is a suitable drug for treating and preventing allodynia, in particular allodynia of the hands and feet, that is or may be induced by antitumoral chemotherapeutic treatment with sorafenib. | 02-20-2014 |
20140066484 | METHODS OF ADMINISTERING PIRFENIDONE THERAPY - The disclosure relates to improved methods of administering pirfenidone therapy when ciprofloxacin is administered concomitantly. | 03-06-2014 |
20140088160 | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6- -fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarbox- amide and administration thereof - A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxo-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed. | 03-27-2014 |
20140155437 | PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME - The present invention provides a prophylactic or therapeutic agent and a prophylactic or therapeutic method superior in the prophylaxis or treatment of Sjogren's syndrome. Provided are a prophylactic or therapeutic agent for Sjogren's syndrome, containing a compound represented by the formula (I): | 06-05-2014 |
20140179745 | TOPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB - The present invention relates to topical ophthalmological pharmaceutical compositions containing regorafenib, a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof but without hydrophobic silica and its process of preparation and its use for treating ophthalmological disorders. | 06-26-2014 |
20140235678 | Topical Ophthalmological Pharmaceutical Composition containing Sorafenib - The present invention relates to topical ophthalmological pharmaceutical compositions containing sorafenib or a pharmaceutically acceptable salt thereof or a polymorph, hydrate or solvate thereof and its process of preparation and its use for treating ophthalmological disorders. | 08-21-2014 |
20140275183 | AGENT FOR REDUCING SIDE EFFECTS OF KINASE INHIBITOR - The present invention relates to an agent for reducing the side effects of kinase inhibitors, the agent containing at least one branched-chain amino acid selected from among isoleucine, leucine and valine or a salt thereof as an active ingredient, and also relates to an anticancer medicine containing at least one branched-chain amino acid selected from among isoleucine, leucine and valine or a salt thereof, and a kinase inhibitor. | 09-18-2014 |
20140296301 | TOPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAGENIB - The present invention relates to topical ophthalmological pharmaceutical compositions containing regorafenib, a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof and its process of preparation and its use for treating ophthalmological disorders. | 10-02-2014 |
20140309263 | BIOMARKERS OF THERAPEUTIC RESPONSIVENESS - The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. | 10-16-2014 |
20140309264 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to compounds of the formula I, | 10-16-2014 |
20140315958 | 4-[4-(AMINO)-3-FLUOROPHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE MONOHYDRATE - The present invention relates to 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders. | 10-23-2014 |
20140357676 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS FOR DRUG SCREENING - A pharmaceutical composition is provided which includes sorafenib and GW5074. This combination therapy inhibits cancer cell growth via c-Raf-PP2A-DAPK signaling transduction pathway in either an in vitro or pre-clinical animal model for orthotopic spontaneous kidney cancer which simulates clinical symptoms. Formation of the bond between c-Raf and GW5074 leads to conformational change which consequently increases the affinity between sorafenib and c-Raf. Binding with the specific drug target facilitates serine 308 dephosphorylation of DAPK by PP2A and induces necrosis in cancer cells. Serine 308 of DAPK protein may also be used as a biomarker for drug screening. A novel pharmaceutical composition is provided which includes sorafenib and GW5074, a protein complex target consisting of c-Raf and DAPK for drug designing, as well as biomarkers including c-Raf protein, DAPK protein and phosphorylation status of DAPK for drug screening. | 12-04-2014 |
20150018393 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS - The present invention provides compositions and methods for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of DAST. | 01-15-2015 |
20150080435 | PHARMACEUTICAL COMPOSITION CONTAINING CRYSTALLINE SORAFENIB TOSYLATE - The present invention relates to an oral solid dosage form, in particular a tablet, comprising sorafenib tosylate polymorphic form III. | 03-19-2015 |
20150111929 | PROCESS FOR PREPARING CRYSTALLINE SORAFENIB TOSYLATE - The present invention provides an industrially suitable process for the preparation of substantially pure 4-{4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide or Sorafenib and its tosylate salt, with a suitable impurity profile and without requirement of any additional purification steps. The present invention also provides Sorafenib base (II) as stable crystalline Form-SSB. | 04-23-2015 |
20150141467 | SOLID FORMS OF ACETIC ACID, COMPOSITIONS, AND USES THEREOF - Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders. | 05-21-2015 |
20150328145 | TOPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB - The present invention relates to topical ophthalmological pharmaceutical compositions containing regorafenib, a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof but without hydrophobic silica and its process of preparation and its use for treating ophthalmological disorders. | 11-19-2015 |
20150335627 | PHARMACEUTICAL COMPOSITION FOR PROMOTING NERVE INJURY RESTORATION AND APPLICATION THEREOF - A pharmaceutical composition for promoting nerve injury restoration and a use thereof are disclosed. Each unit of the pharmaceutical composition contains 0.5 to 8 g of L-ornithine, 1 to 5 g of aspartic acid, 3 to 10 g of arginine and 3 to 10 g of vitamin B | 11-26-2015 |
20160015697 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY - This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes. | 01-21-2016 |